PATENT CLAIM ANALYSIS

Application Number: 16162459
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-04
Patent Classification: ["514", "256000"]

Abstract:
The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I or Formula II, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X 1 , X 2 , X 3 , X 4 , X 5 , Y 1 , Y 2 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12  and R 13  are as defined in the specification. The inventive Formula I and Formula II compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

Claim (Index 16):
A pharmaceutical composition comprising (i) a therapeutically effective amount of at least one compound according to  claim 1  or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof; (ii) in combination with a pharmaceutically acceptable carrier, diluent or excipient.

Metadata:
- Claim Count in Document: 27.0
- Percentile: 97.0
- Lexical Diversity: 2.07576
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15337184', '14426369', '13420988', '13745734', '15355271']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7708119121520378
- 35 USC 102 Novelty (BERT): 0.5310404380332465
- Combined Prediction Score: 0.7468347647401588
- Mean Citation Score: 324.329874
- Max Citation Score: 346.22852
- Similarity Product: 325.33728123937607

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test